Diabetes management is an important segment of modern healthcare, creating a growing need for a diverse range of antidiabetic medicines. From medicines that improve insulin sensitivity to those that increase insulin release or help the body eliminate excess glucose, different drug classes play different roles in managing blood sugar levels.
For pharmaceutical distributors, stockists and aspiring entrepreneurs, understanding these medicine categories is also valuable when evaluating opportunities in the Diabetic PCD Pharma Franchise market. A strong understanding of antidiabetic formulations helps businesses assess product portfolios, understand market requirements and identify suitable pharmaceutical franchise partnerships.
Arlak Corazon, a division of Arlak Biotech, offers a range of diabetic formulations, including single-ingredient medicines and combination products. This article explains the major classes of diabetes medicines, how they work, their uses and how they relate to the diabetic pharmaceutical franchise segment.
Diabetes medicines are pharmaceutical formulations used to manage blood glucose levels in people with diabetes. Their purpose is to help the body regulate glucose by improving insulin action, supporting insulin secretion, reducing glucose production or increasing glucose removal.
The choice of medicine depends on several factors, including:
Blood glucose levels and HbA1c
Kidney and cardiovascular health
Other existing medical conditions
Patient response to treatment
Risk of side effects and low blood sugar
Type 2 diabetes is commonly managed with oral antidiabetic medicines, injectable therapies or a combination of treatments. Type 1 diabetes, on the other hand, requires insulin because the body produces little or no insulin.
Different antidiabetic medicine classes work through different biological mechanisms. Understanding these differences provides a clearer picture of the formulations available in the pharmaceutical market.
How they work: Biguanides primarily reduce glucose production in the liver. They also improve the body's sensitivity to insulin, helping cells use glucose more effectively.
Common uses: Metformin is widely used as a first-line treatment option for many people with type 2 diabetes, depending on individual clinical circumstances.
Products from Arlak Corazon Cardiac Diabetic PCD Pharma Franchise:
ZULIP-500 SR – Metformin 500 mg
ZULIP-1000 SR – Metformin 1000 mg
Depazide-10M – Dapagliflozin 10 mg with Metformin 500 mg
LINAWISE-M – Linagliptin with Metformin
ZULIP-G2 – Glimepiride with Metformin
Metformin is an important component of several combination formulations, making it a key category within the antidiabetic medicine portfolio.
How they work: Sulfonylureas stimulate the beta cells of the pancreas to release more insulin. This helps lower blood glucose levels.
Common uses: These medicines are prescribed for managing type 2 diabetes when additional insulin secretion is required. They can cause hypoglycaemia, so appropriate patient selection and monitoring are important.
Products from Arlak Corazon Cardiac Diabetic PCD Pharma Franchise:
COPRIDE-2 – Glimepiride 2 mg
COPRIDE-3 – Glimepiride 3 mg
COPRIDE-4 – Glimepiride 4 mg
ZULIP-G1 – Glimepiride with Metformin
ZULIP-G2 – Glimepiride with Metformin
CORAVOG-GM2 – Glimepiride, Metformin and Voglibose
These formulations represent both single-ingredient and combination options within the sulfonylurea segment.
How they work: Dipeptidyl peptidase-4 (DPP-4) inhibitors increase the activity of incretin hormones. These hormones help the body release insulin in response to meals and reduce glucagon secretion when glucose levels are elevated.
Common uses: DPP-4 inhibitors are used in the management of type 2 diabetes, either alone or in combination with other antidiabetic medicines.
Products from Arlak Corazon Cardiac Diabetic PCD Pharma Franchise:
TENETIN-20 – Teneligliptin 20 mg
Z-VIL-50 – Vildagliptin 50 mg
LINAWISE-5 – Linagliptin 5 mg
SITAWAR-50 – Sitagliptin 50 mg
SITAWAR-100 – Sitagliptin 100 mg
TENETIN-M FORTE – Teneligliptin with Metformin
LINAWISE-M – Linagliptin with Metformin
SITAWAR-M – Sitagliptin with Metformin
The availability of different DPP-4 inhibitor molecules and combination formulations allows a pharmaceutical portfolio to cover multiple product requirements in this category.
How they work: Sodium-glucose cotransporter-2 (SGLT2) inhibitors act on the kidneys. They reduce glucose reabsorption, allowing more glucose to leave the body through urine.
Common uses: These medicines are used to manage type 2 diabetes. Certain medicines in this class also have established benefits in specific patients with heart failure or chronic kidney disease, depending on the molecule and approved indication.
Products from Arlak Corazon Cardiac Diabetic PCD Pharma Franchise:
DEPAZIDE-5 – Dapagliflozin 5 mg
DEPAZIDE-10 – Dapagliflozin 10 mg
EMPAWISH-10 – Empagliflozin 10 mg
EMPAWISH-25 – Empagliflozin 25 mg
DEPAZIDE-10M – Dapagliflozin with Metformin
Z-VIL-D – Vildagliptin with Dapagliflozin
SITAWAR-D – Dapagliflozin with Sitagliptin
SGLT2 inhibitors have become an important category in contemporary type 2 diabetes management, particularly because of their additional benefits for selected patients.
How they work: Alpha-glucosidase inhibitors slow the breakdown of complex carbohydrates in the intestine. This delays glucose absorption and helps reduce the rise in blood sugar after meals.
Common uses: Voglibose is used to help manage post-meal blood glucose levels in people with type 2 diabetes.
Products from Arlak Corazon Cardiac Diabetic PCD Pharma Franchise:
CORAVOG 0.2 – Voglibose 0.2 mg
CORAVOG 0.3 – Voglibose 0.3 mg
CORAVOG-R 0.2/0.5 – Voglibose with Repaglinide
CORAVOG-R 0.2/1 – Voglibose with Repaglinide
CORAVOG-GM2 – Glimepiride, Metformin and Voglibose
CORAVOG-GM3 – Glimepiride, Metformin and Voglibose
Voglibose-based formulations add another mechanism of glucose management to a diabetic medicine portfolio.
How they work: Thiazolidinediones improve insulin sensitivity by acting on receptors involved in regulating glucose and fat metabolism. This helps muscle and fat cells respond more effectively to insulin.
Common uses: Pioglitazone is used in selected patients with type 2 diabetes. It may cause fluid retention and is not suitable for everyone, particularly certain patients with heart failure.
Products from Arlak Corazon Cardiac Diabetic PCD Pharma Franchise:
COGLIT-15 – Pioglitazone 15 mg
Z-VIL-P – Vildagliptin with Pioglitazone
TENETIN-P – Teneligliptin with Pioglitazone
ZULIP-GP2 – Glimepiride, Metformin and Pioglitazone
Pioglitazone-based products represent the insulin-sensitising segment of the company's listed diabetic formulations.
How they work: Meglitinides stimulate insulin release from the pancreas. They act relatively quickly and are generally taken around mealtimes as prescribed.
Common uses: Repaglinide is used to help control post-meal blood glucose levels in people with type 2 diabetes.
Products from Arlak Corazon Cardiac Diabetic PCD Pharma Franchise:
CORAVOG-R 0.2/0.5 – Voglibose with Repaglinide 0.5 mg
CORAVOG-R 0.2/1 – Voglibose with Repaglinide 1 mg
These combination formulations bring together two different mechanisms: delayed carbohydrate absorption and stimulated insulin release.
How they work: Insulin replaces or supplements the hormone that helps glucose move from the bloodstream into the body's cells. Different insulin preparations have different onset times and durations of action.
Common uses: Insulin is essential for people with type 1 diabetes and may also be required by people with type 2 diabetes when other treatments are insufficient or in particular clinical situations.
Insulin is an important part of the wider diabetes treatment market. However, it should not be assumed to be part of every oral antidiabetic product portfolio. Buyers should check the current company catalogue for the specific insulin range and formulations available.
| Medicine class | Primary action | Examples |
|---|---|---|
| Biguanides | Reduce glucose production in the liver | Metformin |
| Sulfonylureas | Stimulate insulin release | Glimepiride |
| DPP-4 inhibitors | Support glucose-dependent insulin release | Sitagliptin, Teneligliptin |
| SGLT2 inhibitors | Increase glucose removal through urine | Dapagliflozin, Empagliflozin |
| Alpha-glucosidase inhibitors | Delay carbohydrate absorption | Voglibose |
| Thiazolidinediones | Improve insulin sensitivity | Pioglitazone |
| Meglitinides | Stimulate mealtime insulin release | Repaglinide |
| Insulin preparations | Replace or supplement insulin | Different insulin formulations |
Type 2 diabetes involves several metabolic processes, which means one medicine may not always provide sufficient glucose control. Healthcare professionals may therefore prescribe combinations of medicines that work through different mechanisms.
For example:
Metformin + Glimepiride: Combines reduced liver glucose production with increased insulin release.
Metformin + DPP-4 inhibitor: Combines improved insulin sensitivity with incretin-based action.
Metformin + Dapagliflozin: Combines reduced glucose production with increased urinary glucose excretion.
Glimepiride + Metformin + Voglibose: Combines insulin stimulation, improved glucose regulation and delayed carbohydrate absorption.
Arlak Corazon, the best Cardiac Diabetic PCD Pharma Franchise have listed formulations which include combinations such as ZULIP-G1, LINAWISE-M, DEPAZIDE-10M, SITAWAR-M and CORAVOG-GM2. These examples demonstrate the range of combinations represented in its diabetic portfolio.
Combination therapy must always be selected by a qualified healthcare professional according to the patient's clinical needs. The availability of a formulation does not mean it is suitable for every person with diabetes.
The diabetic pharmaceutical segment offers opportunities for businesses interested in distributing and marketing medicines used in long-term diabetes management.
A Diabetic PCD Pharma Franchise allows an authorised business partner to market and distribute a company's diabetic medicine range within an agreed territory, subject to the terms of the franchise arrangement.
This business model can be relevant to:
Pharma distributors looking to expand their product portfolio.
Medical representatives planning to establish an independent business.
Entrepreneurs interested in the pharmaceutical distribution sector.
Existing PCD franchise partners seeking additional therapeutic categories.
Pharma stockists looking to serve healthcare professionals and pharmacies.
The market requires more than simply having products available. A well-planned business also needs product knowledge, reliable supply arrangements, regulatory compliance and an understanding of local demand.
Choosing a pharmaceutical franchise partner is an important business decision. Before entering an agreement, consider the following factors.
A portfolio covering different antidiabetic medicine classes can help business partners address a wider range of product requirements. Check whether the company offers single-ingredient and combination formulations.
Review product compositions, strengths, pack sizes, manufacturing details and applicable regulatory documentation. Ensure that all products are appropriately authorised and supported by the required documentation.
Arlak Corazon offer territory-based or monopoly arrangements for its Cardiac Diabetic PCD Pharma Franchise. Do understand exactly which products and geographical areas are covered, how exclusivity is defined and whether the terms are provided in writing.
Consistent product availability is important for pharmaceutical distribution. Discuss order requirements, dispatch timelines, payment terms, stock availability and procedures for handling damaged or expired products.
Ask about the promotional materials and business support available to franchise partners. These may include visual aids, product literature, MR bags, visiting cards and other marketing resources, depending on the company's current policy.
Evaluate pricing, minimum order quantities, margins, credit arrangements, expiry policies and other commercial conditions before making a decision. Do not base a franchise decision on promised returns or projected profits alone.
Arlak Corazon is a division of Arlak Biotech focused on cardiac and diabetic pharmaceutical formulations. The company offers a PCD pharma franchise opportunity for business partners interested in these therapeutic segments.
Its diabetic product portfolio includes several commonly prescribed antidiabetic medicine categories, such as:
Metformin-based formulations: ZULIP-500 SR and ZULIP-1000 SR.
Glimepiride formulations: COPRIDE-2, COPRIDE-3 and COPRIDE-4.
DPP-4 inhibitor formulations: TENETIN-20, Z-VIL-50, LINAWISE-5 and SITAWAR products.
SGLT2 inhibitor formulations: DEPAZIDE and EMPAWISH products.
Voglibose-based formulations: CORAVOG products.
Pioglitazone formulations: COGLIT-15 and combination products.
The portfolio also includes combination formulations designed around different mechanisms of glucose management.
For distributors and entrepreneurs exploring a Diabetic PCD Pharma Franchise, Arlak Corazon provides an opportunity to evaluate a dedicated diabetic medicine range alongside its cardiac portfolio.
Prospective franchise partners can contact the company to discuss product availability, territory requirements, commercial terms and the support currently offered.
Common classes include biguanides, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, alpha-glucosidase inhibitors, thiazolidinediones and meglitinides. Insulin is also an essential treatment for many people with diabetes.
Metformin is commonly used as an initial treatment for many people with type 2 diabetes. However, treatment decisions depend on individual health conditions, cardiovascular and kidney risks, blood glucose levels and other clinical considerations.
DPP-4 inhibitors work by increasing the activity of incretin hormones, which help regulate insulin and glucagon. SGLT2 inhibitors work through the kidneys, increasing the amount of glucose removed through urine.
Combination medicines contain two or more active ingredients that work through different mechanisms. They may help healthcare professionals address multiple aspects of glucose regulation through a single formulation.
Arlak Corazon's listed diabetic range includes metformin, glimepiride, voglibose, pioglitazone, teneligliptin, vildagliptin, linagliptin, sitagliptin, dapagliflozin, empagliflozin and repaglinide formulations, including several combinations.
A Diabetic PCD Pharma Franchise is a business arrangement in which an authorised partner markets and distributes a company's diabetic medicines within an agreed territory and under defined contractual terms.
Interested businesses can contact Arlak Corazon to discuss its product portfolio, territory availability, documentation, minimum order requirements and franchise terms before proceeding.
Diabetes medicines represent a diverse pharmaceutical segment, with different drug classes addressing different aspects of blood glucose regulation. Understanding their mechanisms, uses and formulations is valuable not only for healthcare awareness but also for businesses evaluating opportunities in pharmaceutical distribution.
For entrepreneurs and distributors exploring the Diabetic PCD Pharma Franchise market, selecting a company with a relevant product portfolio, transparent commercial terms and dependable business support is an important starting point.
Arlak Corazon offers a range of cardiac and diabetic formulations for prospective franchise partners interested in developing their presence in these therapeutic segments.
Explore the diabetic product range and connect with Arlak Corazon to learn more about its PCD Pharma Franchise opportunity.
Medical disclaimer: This article is for general educational and pharmaceutical business information. It does not replace professional medical advice, diagnosis or treatment. Diabetes medicines should only be used under the guidance of a qualified healthcare professional. Product availability and compositions should be confirmed against the latest company catalogue.
Explore a cardiac-diabetic PCD pharma franchise with Arlak Corazon. Contact the company to discuss your preferred territory, product requirements, and current franchise terms.
Contact information
Name – Arlak Corazon
Phone Numbers – +91-7087571536
Email - arlakcorazon@gmail.com
Address: SCO 5-6, Wadhawa Nagar, Near Hotel SunparkKalka Highway, Zirakpur, Punjab, India – 140603
Read More about -
Benefits of choosing monopoly based PCD Pharma Franchise
PCD Pharma Franchise in India: Investment, Products & Business Scope
Growing Demand of Cardiac Medicines
Best PCD Pharma Franchise in Maharashtra